Search results
Showing 1531 to 1545 of 7785 results
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)
Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.
Nintedanib for treating idiopathic pulmonary fibrosis (TA379)
Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.
NICE is unable to make a recommendation about the use in the NHS of eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy. This is because Novartis did not provide an evidence submission
Show all sections
Sections for TA382
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable. This is because Celgene technology did not provide an evidence submission.
Show all sections
Sections for TA362
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.